List of Excipients in Branded Drug MIFEPREX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Danco Laboratories LLC	MIFEPREX	mifepristone	64875-001	CELLULOSE, MICROCRYSTALLINE
Danco Laboratories LLC	MIFEPREX	mifepristone	64875-001	MAGNESIUM STEARATE
Danco Laboratories LLC	MIFEPREX	mifepristone	64875-001	POVIDONE
Danco Laboratories LLC	MIFEPREX	mifepristone	64875-001	SILICON DIOXIDE
Danco Laboratories LLC	MIFEPREX	mifepristone	64875-001	STARCH, CORN

Mifeprex Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Mifeprex is a 200 mg mifepristone tablet marketed by Danco Laboratories under FDA NDA 020687. Its excipient system is conventional and readily reproducible, which limits formulation-based exclusivity but creates opportunities for lower-cost generics, co-packaged mifepristone-misoprostol products, improved supply reliability, and differentiated patient-service models. The principal commercial barriers are regulatory controls, political and litigation risk, distribution access, and manufacturing scale rather than complex formulation technology.

What excipients are used in Mifeprex tablets?

Mifeprex contains five inactive ingredients:

Excipient	Functional role
Microcrystalline cellulose	Diluent, compression aid, tablet structure
Croscarmellose sodium	Superdisintegrant
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow modifier

The product is a single 200 mg immediate-release tablet. The FDA label does not identify a modified-release coating, enteric system, flavoring system, or specialized delivery technology. The formulation therefore relies on standard direct-compression or wet-granulation excipient technology rather than a proprietary delivery platform. [1]

The excipient profile is commercially attractive because all five materials are widely used in oral solid-dose manufacturing. Multiple qualified suppliers generally exist for each material, reducing single-source procurement risk. The critical development work is likely to involve blend uniformity, tablet hardness, disintegration, dissolution, stability, and control of mifepristone polymorphic and particle-size behavior.

How does the Mifeprex formulation affect generic development?

A generic developer can pursue a conventional 200 mg immediate-release tablet with the same active ingredient and comparable performance. The formulation does not present the technical complexity associated with liposomes, long-acting injectables, biologics, osmotic systems, or enteric delivery.

The main development issues are:

1. Dissolution and bioequivalence. Excipient levels can alter wetting, disintegration, dissolution, and gastrointestinal absorption.
2. Content uniformity. Mifepristone is present at a relatively high tablet load, but powder flow, segregation, and lubrication remain important.
3. Chemical and physical stability. Moisture exposure, tablet porosity, packaging, and particle-size distribution can affect shelf life.
4. Manufacturing reproducibility. Magnesium stearate mixing time and compression force can materially change tablet dissolution.
5. Regulatory sameness. A generic can use different inactive ingredients if the formulation satisfies applicable FDA requirements and does not create safety, quality, or performance concerns.

The generic opportunity is therefore primarily a scale, cost, and access opportunity. Excipient substitution alone is unlikely to create a durable patent position unless it supports a genuinely differentiated formulation with unexpected performance.

What formulation patents protect Mifeprex?

The core mifepristone composition-of-matter protection is expired. Mifepristone was developed decades ago, and the current commercial opportunity is not protected by a live basic compound patent.

Public FDA product information identifies Mifeprex as an immediate-release tablet and does not establish a commercially significant, formulation-based exclusivity barrier comparable to a long-acting formulation or complex drug-delivery system. [1] A complete freedom-to-operate opinion would require a live patent search covering U.S. and foreign family members, continuation applications, manufacturing claims, and third-party formulations. The relevant business conclusion is that formulation patents, rather than the original mifepristone molecule, would be the principal route for new exclusivity.

Potential patentable subject matter includes:

• A low-moisture tablet formulation with improved stability.
• A specific particle-size or polymorph control strategy.
• A co-packaged regimen with mifepristone and misoprostol.
• A unit-dose blister configuration that improves dispensing and compliance.
• A formulation optimized for remote dispensing or simplified administration.
• A manufacturing process that reduces degradation or improves content uniformity.
• A tablet designed for alternative administration, subject to clinical and regulatory support.

A patent covering only routine selection of microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, or silicon dioxide would face meaningful obviousness risk. Stronger claims would require comparative data showing improved dissolution, stability, manufacturability, or clinical usability.

What is the Orange Book status of Mifeprex?

Mifeprex is listed in FDA product databases under NDA 020687. The product’s original regulatory exclusivity and core patent position are historical rather than current commercial barriers. FDA-approved generic mifepristone products have entered the U.S. market, confirming that the product is not insulated from ANDA competition. [2]

The key regulatory distinction is between:

• NDA approval: Mifeprex, sponsored by Danco Laboratories.
• ANDA approval: Generic mifepristone products, including the GenBioPro product.
• REMS controls: A regulatory risk-management framework that has applied to mifepristone and was modified by FDA.
• Patent or regulatory exclusivity: The principal barriers that normally delay ANDA launch.

FDA announced in January 2023 that it would modify the mifepristone REMS program. Certified pharmacies became eligible to dispense mifepristone, and the prior in-person dispensing requirement was removed under the revised framework. [3] The change expanded commercial distribution options but did not eliminate certification, prescriber, pharmacy, documentation, and dispensing requirements.

When does Mifeprex lose exclusivity?

Mifeprex’s original seven-year orphan-drug exclusivity period expired long ago. The underlying mifepristone patent protection also expired before the current generic market developed. The product’s present commercial position depends on brand recognition, distribution, supply reliability, regulatory compliance, and market access rather than unexpired basic patent rights.

Milestone	Date or status
FDA approval of Mifeprex	September 2000
Original Mifeprex REMS framework	Established at approval
GenBioPro generic approval	2019
FDA REMS modification	January 2023
Removal of in-person dispensing requirement	Effective under revised FDA framework
Current exclusivity profile	No meaningful basic-molecule exclusivity

The absence of basic patent exclusivity does not mean that every formulation or process claim is unprotected. It means that commercial entry cannot generally be blocked by the original mifepristone molecule patent.

Which companies are challenging Mifeprex commercially?

The principal U.S. generic competitor is GenBioPro, which markets mifepristone tablets. Other manufacturers may pursue or supply mifepristone through ANDA or related regulatory pathways, but the competitive field is constrained by the product’s REMS framework, limited demand predictability, political exposure, and distribution restrictions.

The competitive structure includes:

Participant	Commercial role
Danco Laboratories	Mifeprex sponsor and brand supplier
GenBioPro	FDA-approved generic mifepristone supplier
Misoprostol manufacturers	Suppliers of the companion prostaglandin product
Certified pharmacies and specialty distributors	Dispensing and distribution channels
Telehealth and reproductive-health providers	Patient acquisition and prescribing channels

Commercial competition is not determined only by tablet cost. A supplier must maintain reliable availability, meet controlled distribution requirements, support certified dispensing partners, and manage heightened litigation and public-policy risk.

What excipient strategies create commercial opportunities?

Low-cost equivalent tablet

The most direct opportunity is a conventional generic tablet using pharmacopeial-grade excipients and a high-throughput manufacturing process. Savings can come from:

• Higher tablet press utilization.
• Fewer granulation steps.
• Reduced excipient inventory complexity.
• Domestic or regional dual sourcing.
• Automated visual inspection and packaging.
• High-density blister or bottle configurations.

A low-cost product would compete on acquisition price, supply continuity, and payer or provider contracting.

Stability-enhanced formulation

Mifepristone products must maintain potency and dissolution through distribution and storage. A formulation that improves resistance to moisture, heat, or packaging excursions could support a differentiated regulatory and commercial position.

Potential approaches include:

• Lower-moisture excipient grades.
• Optimized tablet porosity.
• Protective film coating.
• High-barrier blister packaging.
• Desiccant-supported bottle packaging.
• Controlled lubricant concentration.
• Improved particle-size and blend control.

Packaging may provide a more practical commercial advantage than a new excipient system. A stability improvement that extends shelf life or reduces temperature-control requirements could reduce product loss across pharmacies, clinics, and mail-order channels.

Mifepristone-misoprostol co-pack

Medication abortion commonly involves mifepristone followed by misoprostol. A co-pack could improve dispensing accuracy, reduce coordination burdens, and support telehealth or pharmacy fulfillment. The opportunity includes:

• A unit-of-use regimen pack.
• Calendar or time-labeled packaging.
• Separate protection for the two products.
• Patient instructions and adherence materials.
• Serialized packaging for pharmacy and inventory controls.

A co-pack would not automatically obtain the same regulatory treatment as a new drug product. The sponsor would need to establish the appropriate FDA pathway, manufacturing controls, labeling, stability, and compatibility requirements. The commercial value is likely greater in logistics and patient experience than in excipient novelty.

Alternative dosage forms

Potential products include orally disintegrating tablets, sublingual systems, buccal tablets, and lower-swallowing-burden formats. These could support patients with nausea, swallowing difficulty, or limited access to water.

The technical risks are substantial. A new dosage form may alter absorption, require new clinical or bioequivalence evidence, introduce taste and mucosal-tolerability problems, and fall outside the simplest ANDA strategy. The opportunity is stronger for a 505(b)(2) product or a branded lifecycle product than for a basic generic.

How strong is the Mifeprex patent estate?

The legacy patent estate is commercially weak against conventional generic entry because the core compound protection has expired and the product is an established immediate-release tablet. A new entrant’s principal exposure is more likely to arise from regulatory compliance, supply-chain execution, and litigation over newly asserted formulation or process claims than from the original Mifeprex patent position.

Patent-estate factor	Assessment
Core mifepristone composition	Expired
Conventional 200 mg tablet	Limited opportunity for broad new protection
Excipient selection	Usually weak unless supported by unexpected results
Packaging and co-pack configuration	Potentially protectable, but claim scope may be narrow
Manufacturing process	Potentially valuable if it improves quality or cost
Alternative dosage forms	Greater differentiation, but higher regulatory burden
Foreign protection	Jurisdiction-specific and commercially variable

A strong new patent program would focus on measurable performance gains, not a list of standard excipients. Stability data, dissolution comparisons, process capability, and commercial-scale manufacturing results would be important evidence.

What generic entry risks exist for Mifeprex?

Paragraph IV challenges

The historic patent barriers to mifepristone generic entry have already been overcome. An ANDA applicant would still need to address any patents listed for the reference product and certify appropriately. For a product with no meaningful remaining basic patent barrier, the litigation risk shifts toward:

• Newly issued formulation patents.
• Manufacturing-process patents.
• Co-pack or regimen patents.
• Labeling and method-of-use disputes.
• State-level distribution restrictions.
• Contract and supply disputes.

A Paragraph IV certification can create litigation exposure, but it can also support early market entry when the challenged patents are weak or expired.

Regulatory and operational risk

The most material risks are:

• Failure to satisfy the modified REMS requirements.
• Pharmacy certification or distribution interruption.
• Product shortages.
• Manufacturing observations or warning letters.
• Inadequate stability data.
• Labeling noncompliance.
• Political or judicial action affecting access.

These risks can delay revenue even when patent barriers are absent.

What patent litigation affects Mifeprex?

The most important recent federal litigation concerned FDA’s approval and regulation of mifepristone, not an excipient patent dispute. In June 2024, the U.S. Supreme Court held in FDA v. Alliance for Hippocratic Medicine that the plaintiffs lacked standing to challenge FDA’s actions. The decision left the FDA approvals and the 2023 REMS modifications in place. [4]

The case reduced immediate federal uncertainty over the product’s FDA status. It did not eliminate the possibility of future regulatory, state-law, access, or commercial disputes. For formulation developers, the decision supports continued investment in U.S. products but does not remove the need for a compliance-focused launch plan.

Is biosimilar risk relevant to Mifeprex?

No. Mifepristone is a chemically synthesized small molecule, not a biologic. Biosimilar approval pathways under the Public Health Service Act do not apply. Competitive products use generic-drug pathways, including ANDAs, or potentially a 505(b)(2) application for a materially different formulation or route of administration.

This distinction matters commercially. Mifepristone competition is driven by generic substitution, formulation differentiation, manufacturing cost, distribution access, and regulatory compliance rather than biosimilar interchangeability.

How does Mifeprex compare with competing reproductive-health products?

Product category	Formulation complexity	Primary commercial barrier	Excipient opportunity
Mifeprex mifepristone tablet	Low to moderate	REMS, access, supply	Stability, co-pack, low-cost generic
Misoprostol tablet	Low	Generic pricing and supply	Heat stability, packaging, regimen pack
Combined mifepristone-misoprostol pack	Moderate	FDA pathway and coordinated labeling	Unit-of-use packaging and adherence
Long-acting contraceptive	Moderate to high	Device, clinical development, manufacturing	Delivery system and device patents
Biologic reproductive-health therapy	High	Biosimilar and manufacturing complexity	Not directly comparable

Mifeprex offers a simpler technical platform but a more sensitive commercial environment. Misoprostol is generally easier to source and manufacture, making combined packaging and reliable regimen fulfillment more important than a novel tablet excipient.

What are the geographic coverage and licensing opportunities?

The United States is the highest-value market for an excipient or formulation strategy tied to Mifeprex because FDA approval, REMS compliance, pharmacy certification, and domestic litigation directly affect access. Foreign markets have separate approvals, labeling, patent statuses, distribution models, and abortion-law constraints.

Licensing opportunities include:

• Regional supply agreements for mifepristone tablets.
• Contract manufacturing and packaging.
• Co-pack rights with misoprostol suppliers.
• Stability-enhanced formulation licenses.
• Certified-pharmacy distribution platforms.
• Technology transfer for high-barrier blister packaging.
• Rights to alternative dosage forms outside the United States.

A licensee should value manufacturing redundancy and regulatory execution more heavily than a broad but weak excipient patent. The strongest asset would combine a defensible formulation or packaging claim with validated commercial-scale production and a compliant distribution network.

What revenue exposure does Mifeprex create?

Revenue exposure is concentrated in U.S. access and demand continuity. A generic or differentiated product can capture value through several models:

1. Commodity generic supply: Low margin per tablet, higher volume, and contract-driven demand.
2. Branded generic: Moderate premium based on availability, packaging, and provider support.
3. Co-packaged regimen: Higher value per treatment course through logistics and convenience.
4. Specialty distribution: Revenue from certified pharmacy and telehealth fulfillment.
5. International licensing: Lower direct operating cost but greater country-specific regulatory complexity.

The financial risk is asymmetric. Tablet manufacturing costs are relatively manageable, but a disruption in certification, supply, or legal access can affect the entire addressable market. Commercial plans should therefore prioritize dual sourcing, inventory buffers, validated alternate sites, and high-barrier packaging.

Key Takeaways

• Mifeprex is a 200 mg immediate-release mifepristone tablet with five conventional excipients.
• The core mifepristone patent and original exclusivity protections are expired.
• FDA-approved generic competition confirms that the main market barrier is not basic molecule protection.
• The strongest excipient opportunities involve stability, dissolution control, manufacturability, and packaging rather than routine excipient substitution.
• A mifepristone-misoprostol co-pack is a commercially credible lifecycle strategy.
• Alternative dosage forms could create stronger differentiation but would likely require a more complex FDA pathway.
• Mifeprex is not subject to biosimilar competition because it is a small-molecule drug.
• REMS compliance, pharmacy certification, supply continuity, and litigation risk are more important than legacy patent protection.
• The Supreme Court’s 2024 standing decision left FDA approval and the 2023 REMS modifications in place.
• Licensing value is highest where formulation or packaging technology is paired with reliable manufacturing and compliant distribution.

FAQs

Can a new excipient alone create exclusivity for mifepristone?

Usually not. A routine substitution of microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, or colloidal silicon dioxide would face substantial obviousness risk. Stronger protection would require unexpected stability, dissolution, bioavailability, or manufacturing results.

Is a mifepristone oral film commercially viable?

It could be, but the product would likely require formulation, taste-masking, dose-uniformity, stability, and bioequivalence work. An oral film may be better positioned as a 505(b)(2) lifecycle product than as a simple ANDA equivalent.

Can mifepristone and misoprostol be sold in one blister?

A coordinated unit-of-use package is commercially possible, but the sponsor must address packaging compatibility, labeling, stability, dosing instructions, and the applicable FDA regulatory pathway. The products should not be assumed to have identical storage or handling requirements.

Does mifepristone require cold-chain distribution?

Mifeprex labeling does not establish a conventional cold-chain requirement. The commercial priority is controlled storage within labeled conditions, supported by stability data and protective packaging.

What is the best patent strategy for a new Mifeprex competitor?

The strongest strategy would combine a measurable formulation or packaging improvement with process claims, validated stability data, and jurisdiction-specific freedom-to-operate analysis. A broad claim covering standard excipients alone is unlikely to provide durable protection.

References

1. U.S. Food and Drug Administration. (2023). Mifeprex (mifepristone) tablets, 200 mg: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020687s023lbl.pdf

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: Mifeprex and mifepristone products. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2023, January 3). FDA updates mifepristone REMS program to allow certified pharmacies to dispense mifepristone. https://www.fda.gov/news-events/press-announcements/fda-updates-mifepristone-rems-program

4. Supreme Court of the United States. (2024). Food and Drug Administration v. Alliance for Hippocratic Medicine, 602 U.S. ___. https://www.supremecourt.gov/opinions/23pdf/23-235_n7ip.pdf